A5021092277- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Blood transfusion and management
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Eosinophilic Disorders and Syndromes
- Blood groups and transfusion
- Retinoids in leukemia and cellular processes
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Blood disorders and treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Histone Deacetylase Inhibitors Research
- HER2/EGFR in Cancer Research
- Hemoglobinopathies and Related Disorders
- Immunodeficiency and Autoimmune Disorders
- Cancer therapeutics and mechanisms
- Blood donation and transfusion practices
- Lung Cancer Treatments and Mutations
- Economic and Financial Impacts of Cancer
- Venous Thromboembolism Diagnosis and Management
The Barbara Ann Karmanos Cancer Institute
2015-2024
Wayne State University
2015-2024
Dana-Farber Cancer Institute
1987-2017
University of Chicago
1998-2017
American Society of Clinical Oncology
2000-2017
Centre Hospitalier Universitaire Sainte-Justine
2017
Université de Montréal
2017
Cornell University
1999-2016
University Hospital Heidelberg
2016
Johns Hopkins University
2003-2016
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, product of Philadelphia chromosome. Imatinib mesylate, formerly STI571, a selective inhibitor this kinase.
PURPOSE: Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients MDS. PATIENTS AND METHODS: A randomized controlled trial undertaken 191 MDS compare Aza C (75 mg/m 2 /d subcutaneously for 7 days every 28 days) supportive care. defined by French-American-British criteria. New rigorous response criteria were...
To update the 2000 American Society of Clinical Oncology guideline on use hematopoietic colony-stimulating factors (CSF).The Update Committee completed a review and analysis pertinent data published from 1999 through September 2005. Guided by 1996 ASCO clinical outcomes criteria, formulated recommendations based improvements in survival, quality life, toxicity reduction cost-effectiveness.The 2005 agreed unanimously that febrile neutropenia (FN) is an important outcome justifies CSFs,...
About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated cytarabine and an anthracycline. However, such responses are rarely durable conventional postremission therapy is administered. Uncontrolled trials have suggested that intensive may prolong these remissions.We 1088 newly diagnosed AML three days daunorubicin seven randomly assigned patients who had a to receive four courses at one doses: 100 mg per square meter...
All-trans-retinoic acid induces complete remission in acute promyelocytic leukemia. However, it is not clear whether induction therapy with all-trans-retinoic superior to chemotherapy alone or maintenance treatment improves outcome.
Article Tools ASCO SPECIAL ARTICLE OPTIONS & TOOLS Export Citation Track Add To Favorites Rights Permissions COMPANION ARTICLES No companion articles CITATION DOI: 10.1200/JCO.2000.18.20.3558 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11032599 2000 Update Recommendations for the Use Hematopoietic Colony-Stimulating Factors: Evidence-Based, Practice Guidelines Howard OzerxHoward OzerSearch by this author , James O. ArmitagexJames ArmitageSearch...
Fludarabine is an effective treatment for chronic lymphocytic leukemia that does not respond to initial with chlorambucil. We compared the efficacy of fludarabine chlorambucil in primary leukemia.
OBJECTIVE: To determine the most effective, evidence-based approach to use of platelet transfusions in patients with cancer. OUTCOMES: Outcomes interest included prevention morbidity and mortality from hemorrhage, effects on survival, quality life, toxicity reduction, cost-effectiveness. EVIDENCE: A complete MedLine search was performed past 20 years medical literature. Keywords transfusion, alloimmunization, threshold thrombocytopenia. The broadened by articles bibliographies selected...
Elderly patients with primary acute myelogenous leukemia (AML) are less likely to enter remission than younger adults, in part because of a higher mortality rate related severe myelosuppression. Granulocyte–macrophage colony-stimulating factor (GM-CSF) has been shown shorten the duration neutropenia and decrease infectious complications when administered after chemotherapy lymphomas solid tumors.
Abstract The National Cancer Institute (NCI)‐sponsored Chronic Lymphocytic Leukemia (CLL) Working Group was convened to develop a set of standardized eligibility, response, and toxicity criteria for clinical trials. We recognized the previous efforts in 1967 published again 1973 as report Leukemia‐Myeloma Task Force [1] 1978 B (CALGB) [2]. have used these reports guidance during current effort. Several noteworthy developments past few years made it necessary modify guidelines. First,...
The impact of azacytidine (Aza C) on the quality life 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221).One hundred ninety-one (mean age, 67.5 years; 69% male) were randomized to receive either Aza C (75 mg/m(2) subcutaneous for 7 days every 4 weeks) or supportive care, care crossing over upon disease progression. Quality by centrally conducted telephone interviews at baseline 50, 106, 182. Overall life, psychological state,...
To evaluate the efficacy and safety of a slow-release formulation cytarabine (DepoCyt; Chiron Corp, Emeryville, CA, Skye Pharma, Inc, San Diego, CA) that maintains cytotoxic concentrations (ara-C) in CSF most patients for more than 14 days.Twenty-eight with lymphoma positive cytology were randomized to receive DepoCyt 50 mg once every 2 weeks or free ara-C twice week 1 month. Patients whose converted negative who did not have neurologic progression received an additional 3 months...
Purpose Because both t(8;21) and inv(16) disrupt core binding factor (CBF) in acute myeloid leukemia (AML) confer relatively favorable prognoses, these cytogenetic groups are often treated similarly. Recent studies, however, have shown different gene profiling for the two groups, underscoring potential biologic differences. Therefore, we sought to determine whether should also be considered separate entities from a clinical standpoint. Patients Methods We analyzed 144 consecutive adults with...
Purpose To develop an evidence-based guideline on central venous catheter (CVC) care for patients with cancer that addresses type, insertion site, and placement as well prophylaxis management of both catheter-related infection thrombosis. Methods A systematic search MEDLINE the Cochrane Library (1980 to July 2012) identified relevant articles published in English. Results The overall quality randomized controlled trial evidence was rated good. There is consistency among meta-analyses...